Financial analysts tracking Foghorn Therapeutics (NASDAQ: FHTX) maintain an average 12-month consensus price target hovering around $11.44, with high estimates reaching up to $14.00 and conservative projections around $9.00. These bullish forecasts are underpinned by the company's pioneering gene transcription modulation platform and ongoing clinical oncology trial expansions.